Tricuspid transcatheter edge-to-edge repair for tricuspid valve regurgitation: a sex-based real-world analysis from the TRI-SPA registry

Aims Impact of sex-related differences on clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) remains underexplored. Methods and results This sub-analysis of the Transcatheter tRicuspid valve repaIr in SPAin (TRI-SPA) registry includes...

Descripción completa

Detalles Bibliográficos
Autores: Ruberti, A, Cepas-Guillen, P, Echarte-Morales, J, Arzamendi, D, Moñivas, V, Carrasco-Chinchilla, F, Pan, MN, Nombela-Franco, L, Pascual, I, Sabatè-Tenas, M, Benito-González, T, Perez, R, Gómez-Blázquez, I, Amat-Santos, IJ, Flores-Umanzor, E, Cruz-González, I, Sánchez-Recalde, A, Alvarez, ABC, Barreiro-Perez, M, Sanchis, L, Li, CH, Caneiro-Queija, B, del Trigo, M, Martinez-Carmona, JD, Mesa-Rubio, D, Jimenez, P, Avanzas, P, Estevez-Loureiro, R, Freixa, X
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p21113
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21113
Access Level:acceso abierto
Palabra clave:Tricuspid regurgitation
Tricuspid transcatheter edge-to-edge repair
Sex differences
Women
Atrial fibrillation
Descripción
Sumario:Aims Impact of sex-related differences on clinical outcomes after tricuspid transcatheter edge-to-edge repair (T-TEER) for severe tricuspid regurgitation (TR) remains underexplored. Methods and results This sub-analysis of the Transcatheter tRicuspid valve repaIr in SPAin (TRI-SPA) registry includes patients who underwent T-TEER for severe TR between June 2020 and May 2023 in Spain. Outcomes were compared by sex. The primary composite endpoint included all-cause mortality, heart failure-related hospitalization, and tricuspid valve re-intervention at 12 months. Secondary endpoints included significant TR recurrence and functional improvement. Among 310 patients (mean age 75.5 +/- 9.1 years) with severe TR treated with T-TEER, 70% were females. Males exhibited more prevalent coronary artery disease (30.4 vs. 12.8%; p < 0.001) and reduced right ventricular (RV) function compared with females (RV fractional area change 34.5 vs. 42.0%; p < 0.001). Women had larger left atrial volume (45.7 vs. 40.8 mL/m(2), p = 0.038). Procedural success was high and comparable among sexes (90.7 vs. 89.3% in females and males, respectively; p = 0.71). No significant difference emerged in relation to the primary composite endpoint (absolute event rate in males 27.5 vs. 16.3% in females; adjusted HR 0.61, 95% CI: 0.31-1.18; p = 0.142). At 12 months, comparable sustained TR reduction (grade <= 2+) rates (67.3% in males vs. 73.5% in females; p = 0.40) and functional improvement (NYHA I/II class 75.0 vs. 82.3%; p = 0.78) were observed. Conclusion In a real-world setting, T-TEER was equally safe and effective in both sexes, achieving comparable procedural success and durable TR reduction.

Similares en LA Referencia